Nass Valley Gateway Ltd (NVG)

[StockHighAlert-]

Nass Valley Gateway LTD is a publicly traded company on the CSE (NVG) and the Frankfurt stock exchange (3NVN) in the Life Sciences category. In 2018, Nass Valley Gateway merged with Advanced Bioceuticals Limited, a company focused on the development of a fully-integrated strategy to bring organic, hemp-based, CBD products to market. These products now will be sold under the Nass Valley Gardens?, DermaPharm?, and The Duchess? brands via retail, wholesale, direct response, and digital sales channels.



ABL has established a successful central clearing house that services over 800,000 patients with chronic pain and is strategically placed to expand to over 5 million patients nationwide.

Our proprietary technology has streamlined our capacity to operate in multiple states under multiple facilities permitted and licensed to offer such services to this vastly growing patient base of patients who are underserviced and deterred by the opioid crisis.

Furthermore, our company invested in a consumer packaged goods CBD product line that is undeniably beneficial for our patients.

With our clearing house capacity to offer additional products and services to our active patients, the use of CBD as an alternative supplement for continued use, we are in a unique position to expand our initiatives in the CBD market.

There are many nuances and deterrence currently in the CBD market including full vertical supply chain vs. demand issues. Many companies rely on third party vendors that fail to execute in quality.

As a result, we have engaged a team of pharmacologists and nutritionists to strategically acquire our own production, manufacturing and distribution under cGMP CFR 111 guidance that can ensure our products are made under pharmaceutical quality testing and validation principles and further allow us to dictate our capacity to expand, without the lack of reliability in the market place.

Our goal is to cross-sell and convert a large portion of our patients to the topical and sublingual CBD alternative treatments and further engage with our patients’ doctors to acquire a triage of care under our compliance program to further provide pain relief.

Our shareholders will appreciate the combined experience of over 50 years in DME and CPG production and delivery, our customized CPG product intimately targeting our DME patients and further expand to additional DME patients and extrapolate our line to further distribution outlets.

Nass Valley Gateway Ltd, by way of ABL, shall have a national presence in CBD through our CPG line, a large volume influx of CBD patients converted from our database, and a supply chain under our control to ensure cGMP quality products are distributed consistently, meeting our expansion targets swiftly by way of future mergers, acquisitions and distribution agreements.